Management of Thrombocytopenia in Patients with Kidney Disease

Initial Assessment and Risk Stratification

The American Society of Hematology recommends assessing bleeding risk by evaluating concurrent coagulopathy, severity of renal impairment affecting drug clearance, active infection, history of bleeding episodes, and need for invasive procedures in patients with kidney disease and thrombocytopenia 1, 2, 3, 4

For patients with platelets ≥50,000/μL, the American College of Chest Physicians recommends continuing full therapeutic anticoagulation without platelet transfusion support if anticoagulation is indicated 2, 3
For patients with platelets 25,000-50,000/μL, the American College of Chest Physicians recommends reducing low molecular weight heparin (LMWH) to 50% of therapeutic dose or using prophylactic dosing 1, 2, 5
For patients with platelets <25,000/μL, the American College of Chest Physicians recommends temporarily discontinuing all anticoagulation unless high thrombotic risk exists 1, 2, 5

The American College of Chest Physicians recommends using argatroban over other nonheparin anticoagulants in patients with renal insufficiency requiring anticoagulation for thrombosis 4

For high-risk thrombotic events, the American College of Chest Physicians recommends full therapeutic LMWH without transfusion support for platelets ≥50,000/μL, and full therapeutic LMWH with platelet transfusion support to maintain platelets ≥40,000-50,000/μL for platelets 40,000-50,000/μL 1, 2, 3
For lower-risk thrombotic events, the American College of Chest Physicians recommends using a dose-modification strategy with 50% or prophylactic-dose LMWH for platelets 25,000-50,000/μL 1, 2

The American College of Chest Physicians recommends never using direct oral anticoagulants (DOACs) in patients with severe thrombocytopenia (<50,000/μL) as data are lacking and bleeding risk is substantially increased 2, 6

The American Society of Hematology recommends monitoring platelet counts daily until stable or improving, and reassessing anticoagulation needs and resuming full therapeutic dosing if indicated when platelets recover to >50,000/μL 1, 2, 5